Mindeudesivir, also known as VV116, VV-116, JT001 and deuremidevir, is a deuterated nucleoside analogue antiviral. It was developed as an orally active antiviral compound and is associated with antiviral activity against SARS-CoV-2. Mindeudesivir is the INN name recognized for the compound.
Mindeudesivir is structurally related to remdesivir and contains a deuterium atom in its heterocyclic nucleoside analogue structure. The compound has been investigated and developed particularly for oral antiviral treatment.
Mindeudesivir is a specialized antiviral pharmaceutical API relevant to COVID-19 antiviral research, nucleoside analogue development and pharmaceutical formulation.
CAS Number: 2647442-33-7
Molecular Formula: C24H30DN5O7
Molecular Weight: 502.54 g/mol
Synonyms: VV116, VV-116, JT001, Deuremidevir
INN: Mindeudesivir
Drug Class: Nucleoside Analogue Antiviral
Therapeutic Area: Antiviral / Infectious Disease
Molecule Type: Deuterated Small Molecule
PubChem lists the compound as C24H31N5O7 because its isotopic notation is represented differently in the database, while the deuterated molecular representation gives C24H30DN5O7 and a molecular weight of approximately 502.5 g/mol.
Mindeudesivir is a nucleoside analogue antiviral. Its molecular design is based on a modified nucleoside analogue that can interfere with viral RNA-dependent replication processes.
Its antiviral research has focused particularly on:
Mindeudesivir has been associated with pharmaceutical research and development involving:
Mindeudesivir/deuremidevir has received regulatory recognition in China, with IUPHAR listing it as an approved drug in China in 2023.
Mindeudesivir has been developed for oral administration, including formulations containing its hydrobromide salt.
Mindeudesivir free base is described as a solid, with a reported molecular weight of approximately 502.54 g/mol for the deuterated form. Commercial research documentation describes the material as white to off-white.
A controlled Mindeudesivir API manufacturing process may involve:
For Mindeudesivir API, analytical characterization may include:
Store Mindeudesivir under controlled pharmaceutical storage conditions, protected from moisture, excessive heat and direct light. Exact storage conditions should be established from validated stability data for the specific API form.
Mindeudesivir is relevant to:
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 99.0–100.5% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.1% |
| pH (1% Solution) | 3.2–3.5 |
| Specific Rotation | +31.5° to +33.5° at 405 nm |
| Melting Point | 171–175°C |